GlobalData on MSN

Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

Hansa will apply to the EMA to convert Idefrix’s conditional approval into full marketing authorisation.

Cynata clears key European regulatory step toward future Phase 3 in acute graft versus host disease

Cynata Therapeutics has received a Positive Opinion from the European Medicines Agency’s Paediatric Committee (PDCO) on its ...
Clinical Pain Advisor

Autoimmune Disease Linked to Poor Outcomes With Myelodysplastic Syndrome

HealthDay News — Having a preexisting autoimmune disease is an independent risk factor for poor outcomes with myelodysplastic syndrome (MDS), according to a study published in the June issue of ...
Nature

Graft Versus Host Disease in Solid Organ Transplantation

Graft versus host disease (GVHD) following solid organ transplantation is a rare but often fatal complication arising when donor immune cells contained within the graft recognise recipient tissues as ...

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of acute Graft-versus-Host Disease

MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of aGvHD ...
Knowridge Science Report

New therapy could help doctors fight deadly blood cancers

Aggressive blood cancers such as acute myeloid leukemia and myelodysplastic syndrome remain among the hardest cancers to treat successfully. These diseases affect the bone marrow, where blood cells ...
WDHN on MSN

Champions of hope fundraiser helps buy new equipment for Southeast Health

DOTHAN, Ala. (WDHN) — Southeast Health has used funds raised during their 2025 Champions of Hope event to buy a blood irradiator, a piece of equipment that is used to treat cancer patients and ...